I

InDex Pharmaceuticals Holding AB
STO:FLERIE

Watchlist Manager
InDex Pharmaceuticals Holding AB
STO:FLERIE
Watchlist
Price: 45 SEK 0.78% Market Closed
Market Cap: 3.5B SEK
Have any thoughts about
InDex Pharmaceuticals Holding AB?
Write Note

Profitability Summary

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

High Profitability Stocks
Pharmaceuticals Industry

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
InDex Pharmaceuticals Holding AB

Revenue
100k SEK
Cost of Revenue
-127m SEK
Gross Profit
-126.9m SEK
Operating Expenses
-111.9m SEK
Operating Income
-238.9m SEK
Other Expenses
48.5m SEK
Net Income
-190.4m SEK

Margins Comparison
InDex Pharmaceuticals Holding AB Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
SE
InDex Pharmaceuticals Holding AB
STO:FLERIE
3.5B SEK
-126 944%
-238 880%
-190 353%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-3%
-83%
-79%
US
Eli Lilly and Co
NYSE:LLY
788.6B USD
81%
35%
19%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
3%
-4%
DK
Novo Nordisk A/S
CSE:NOVO B
3.4T DKK
85%
45%
35%
US
Johnson & Johnson
NYSE:JNJ
384.8B USD
69%
28%
17%
US
Merck & Co Inc
NYSE:MRK
259.4B USD
76%
29%
22%
CH
Roche Holding AG
SIX:ROG
213.6B CHF
73%
32%
20%
UK
AstraZeneca PLC
LSE:AZN
171.2B GBP
82%
21%
13%
CH
Novartis AG
SIX:NOVN
183.5B CHF
75%
29%
33%
US
Pfizer Inc
NYSE:PFE
160.4B USD
71%
22%
7%
Country SE
Market Cap 3.5B SEK
Gross Margin
-126 944%
Operating Margin
-238 880%
Net Margin
-190 353%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Operating Margin
-83%
Net Margin
-79%
Country US
Market Cap 788.6B USD
Gross Margin
81%
Operating Margin
35%
Net Margin
19%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Operating Margin
3%
Net Margin
-4%
Country DK
Market Cap 3.4T DKK
Gross Margin
85%
Operating Margin
45%
Net Margin
35%
Country US
Market Cap 384.8B USD
Gross Margin
69%
Operating Margin
28%
Net Margin
17%
Country US
Market Cap 259.4B USD
Gross Margin
76%
Operating Margin
29%
Net Margin
22%
Country CH
Market Cap 213.6B CHF
Gross Margin
73%
Operating Margin
32%
Net Margin
20%
Country UK
Market Cap 171.2B GBP
Gross Margin
82%
Operating Margin
21%
Net Margin
13%
Country CH
Market Cap 183.5B CHF
Gross Margin
75%
Operating Margin
29%
Net Margin
33%
Country US
Market Cap 160.4B USD
Gross Margin
71%
Operating Margin
22%
Net Margin
7%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
InDex Pharmaceuticals Holding AB Competitors

Country Company Market Cap ROE ROA ROCE ROIC
SE
InDex Pharmaceuticals Holding AB
STO:FLERIE
3.5B SEK
-8%
-8%
-10%
-13%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-441%
-47%
-108%
-64%
US
Eli Lilly and Co
NYSE:LLY
788.6B USD
60%
12%
33%
19%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
-2%
2%
2%
DK
Novo Nordisk A/S
CSE:NOVO B
3.4T DKK
89%
28%
77%
37%
US
Johnson & Johnson
NYSE:JNJ
384.8B USD
20%
8%
18%
13%
US
Merck & Co Inc
NYSE:MRK
259.4B USD
33%
13%
21%
17%
CH
Roche Holding AG
SIX:ROG
213.6B CHF
40%
13%
29%
22%
UK
AstraZeneca PLC
LSE:AZN
171.2B GBP
17%
6%
14%
12%
CH
Novartis AG
SIX:NOVN
183.5B CHF
35%
16%
20%
15%
US
Pfizer Inc
NYSE:PFE
160.4B USD
5%
2%
7%
8%
Country SE
Market Cap 3.5B SEK
ROE
-8%
ROA
-8%
ROCE
-10%
ROIC
-13%
Country JP
Market Cap 776 550.9T JPY
ROE
-441%
ROA
-47%
ROCE
-108%
ROIC
-64%
Country US
Market Cap 788.6B USD
ROE
60%
ROA
12%
ROCE
33%
ROIC
19%
Country UK
Market Cap 440.4B GBP
ROE
-4%
ROA
-2%
ROCE
2%
ROIC
2%
Country DK
Market Cap 3.4T DKK
ROE
89%
ROA
28%
ROCE
77%
ROIC
37%
Country US
Market Cap 384.8B USD
ROE
20%
ROA
8%
ROCE
18%
ROIC
13%
Country US
Market Cap 259.4B USD
ROE
33%
ROA
13%
ROCE
21%
ROIC
17%
Country CH
Market Cap 213.6B CHF
ROE
40%
ROA
13%
ROCE
29%
ROIC
22%
Country UK
Market Cap 171.2B GBP
ROE
17%
ROA
6%
ROCE
14%
ROIC
12%
Country CH
Market Cap 183.5B CHF
ROE
35%
ROA
16%
ROCE
20%
ROIC
15%
Country US
Market Cap 160.4B USD
ROE
5%
ROA
2%
ROCE
7%
ROIC
8%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More
Back to Top